Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jan 30;10(2):278.
doi: 10.3390/cells10020278.

Inducible Pluripotent Stem Cells as a Potential Cure for Diabetes

Affiliations
Review

Inducible Pluripotent Stem Cells as a Potential Cure for Diabetes

Kevin Verhoeff et al. Cells. .

Abstract

Over the last century, diabetes has been treated with subcutaneous insulin, a discovery that enabled patients to forego death from hyperglycemia. Despite novel insulin formulations, patients with diabetes continue to suffer morbidity and mortality with unsustainable costs to the health care system. Continuous glucose monitoring, wearable insulin pumps, and closed-loop artificial pancreas systems represent an advance, but still fail to recreate physiologic euglycemia and are not universally available. Islet cell transplantation has evolved into a successful modality for treating a subset of patients with 'brittle' diabetes but is limited by organ donor supply and immunosuppression requirements. A novel approach involves generating autologous or immune-protected islet cells for transplant from inducible pluripotent stem cells to eliminate detrimental immune responses and organ supply limitations. In this review, we briefly discuss novel mechanisms for subcutaneous insulin delivery and define their shortfalls. We describe embryological development and physiology of islets to better understand their role in glycemic control and, finally, discuss cell-based therapies for diabetes and barriers to widespread use. In response to these barriers, we present the promise of stem cell therapy, and review the current gaps requiring solutions to enable widespread use of stem cells as a potential cure for diabetes.

Keywords: diabetes; immune reset; immunosuppression; inducible pluripotent stem cells; insulin; islet cell transplant.

PubMed Disclaimer

Conflict of interest statement

AMJS serves as a consultant to ViaCyte Inc., Diagon Inc., Protokinetix Inc. and Pelican Therapeutics Inc.

Figures

Figure 1
Figure 1
Embryological differentiation and maturation of islet cells.
Figure 2
Figure 2
Mechanisms of β-cell insulin release and glycemic control. Image adapted from Komatsu et al. (2013) with permission for reuse [56].
Figure 3
Figure 3
Limiting factors for islet cell engraftment after islet cell transplant. Adapted from Shapiro et al. (2011) with permission for reuse [11].
Figure 4
Figure 4
Comparison and advancement of subcutaneous insulin delivery, islet cell transplant, and novel inducible pluripotent stem cell-based islet cell transplant for cure of diabetes.
Figure 5
Figure 5
Steps to achieve widespread use of inducible pluripotent stem cell-based islet cell transplant.

References

    1. Karamanou M., Protogerou A., Tsoucalas G., Androutsos G., Poulakou-Rebelakou E. Milestones in the history of diabetes mellitus: The main contributors. World J. Diabetes. 2016;7:1–7. doi: 10.4239/wjd.v7.i1.1. - DOI - PMC - PubMed
    1. Williams P. Notes on diabetes treated with extract and by grafts of sheep’s pancreas. BMJ. 1894;2:1303.
    1. Banting F.G. Nobel Lecture. [(accessed on 25 May 2020)]; Available online: https://www.nobelprize.org/prizes/medicine/1923/banting/lecture/
    1. Foster N.C., Beck R.W., Miller K.M., Clements M.A., Rickels M.R., DiMeglio L.A., Maahs D.M., Tamborlane W.V., Bergenstal R., Smith E., et al. State of Type 1 Diabetes Management and Outcomes from the T1D Exchange in 2016–2018. Diabetes Technol. Ther. 2019;21:66–72. doi: 10.1089/dia.2018.0384. - DOI - PMC - PubMed
    1. Latres E., Finan D.A., Greenstein J.L., Kowalski A., Kieffer T.J. Navigating Two Roads to Glucose Normalization in Diabetes: Automated Insulin Delivery Devices and Cell Therapy. Cell Metab. 2019;29:545–563. doi: 10.1016/j.cmet.2019.02.007. - DOI - PubMed

Publication types

MeSH terms

LinkOut - more resources